Atay A, Ergul M, Ozturk O, Acun KC, Cagir Y, Durak MB, Yuksel I. Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy. World J Gastroenterol 2025; 31(30): 110112 [PMID: 40904881 DOI: 10.3748/wjg.v31.i30.110112]
Corresponding Author of This Article
Ilhami Yuksel, MD, Professor, Department of Gastroenterology, Faculty of Medicine, Ankara Yildirim Beyazit University, İhsan Dogramaci Cad. Bilkent, Ankara 06800, Türkiye. yukselilhami@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Aug 14, 2025 (publication date) through Oct 22, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Atay A, Ergul M, Ozturk O, Acun KC, Cagir Y, Durak MB, Yuksel I. Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy. World J Gastroenterol 2025; 31(30): 110112 [PMID: 40904881 DOI: 10.3748/wjg.v31.i30.110112]
World J Gastroenterol. Aug 14, 2025; 31(30): 110112 Published online Aug 14, 2025. doi: 10.3748/wjg.v31.i30.110112
Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy
Ali Atay, Mucahit Ergul, Oguz Ozturk, Kadir C Acun, Yavuz Cagir, Muhammed B Durak, Ilhami Yuksel
Ali Atay, Mucahit Ergul, Oguz Ozturk, Kadir C Acun, Ilhami Yuksel, Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye
Yavuz Cagir, Department of Gastroenterology, Ankara Yildirim Beyazit University Yenimahalle Training and Research Hospital, Ankara 06105, Türkiye
Muhammed B Durak, Department of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara 063200, Türkiye
Ilhami Yuksel, Department of Gastroenterology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara 06800, Türkiye
Author contributions: Atay A and Yuksel I conceptualized, planned the design of the study, performed data analysis, interpreted the data, and drafted the manuscript; Atay A, Ergul M, Ozturk O, Acun KC, Cagir Y, Durak MB, and Yuksel I performed the data collection; All authors revised and approved the final version of the submitted manuscript to be submitted.
Institutional review board statement: This study was approved by the Ethics Committee of the Ankara Bilkent City Hospital (No. TABED 1-25-1090) and was conducted according to the Declaration of Helsinki.
Informed consent statement: Due to the retrospective nature of the study and use of de-identified data, informed consent was not obtained. This approach was reviewed and approved by the institutional ethics committee.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-a checklist of items.
Data sharing statement: The technical appendix, statistical code, and dataset are available from the corresponding author at (yukselilhami@hotmail.com). Due to the retrospective nature of the study and use of de-identified data, informed consent was not obtained. This approach was reviewed and approved by the institutional ethics committee.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ilhami Yuksel, MD, Professor, Department of Gastroenterology, Faculty of Medicine, Ankara Yildirim Beyazit University, İhsan Dogramaci Cad. Bilkent, Ankara 06800, Türkiye. yukselilhami@hotmail.com
Received: May 30, 2025 Revised: June 14, 2025 Accepted: July 18, 2025 Published online: August 14, 2025 Processing time: 69 Days and 15.9 Hours
Abstract
BACKGROUND
5-aminosalicylates (5-ASA) are the primary treatment for mild to moderate ulcerative colitis (UC). Maintenance therapy with 5-ASA has been shown to reduce both the risk of relapse and colorectal cancer.
AIM
To evaluate the outcomes of 5-ASA withdrawal due to non-adherence in UC patients while in remission on monotherapy.
METHODS
Adult patients with UC who were followed up between July 2019 and April 2025 were screened. Patients in remission receiving 5-ASA monotherapy who experienced treatment withdrawal due to non-adherence were included in this study.
RESULTS
Among 880 patients with UC, 30 (3.4%) had 5-ASA withdrawal due to non-adherence while in remission on monotherapy. Twelve patients (40%) had disease relapse after a median of 20 months. The rate of patients in remission was 89% in the first year, decreasing to 73% in the second year, and to 64% in the third year. There were no significant differences between patients with and without relapse in terms of demographics, disease extent, remission duration before 5-ASA withdrawal, previous medications, steroid dependence, 5-ASA formulation, baseline inflammatory markers, or partial and endoscopic Mayo scores. Most patients (75%) who experienced relapse were successfully treated with 5-ASA monotherapy, while one-fourth of them required corticosteroids. No patients required biologic agents, hospitalization, or surgical intervention.
CONCLUSION
Intermittent therapy may be safe and feasible for UC patients, especially those in long-term remission, with treatment interruption up to one year considered acceptable.
Core Tip: In this study, 5-aminosalicylate (5-ASA) withdrawal was observed in 3.4% of patients with ulcerative colitis (UC). Almost half of them developed a relapse. The majority of patients who experienced relapse were treated with 5-ASA monotherapy, while one-fourth of them required corticosteroids. No patients required biological agents, hospitalization, or surgery. Based on our long-term real-world data, intermittent therapy may represent a potentially safe and feasible strategy in terms of relapse risk in patients with UC. Notably, in patients who have sustained long-term clinical remission, a treatment interruption of up to one year may be considered safe.
